Gina Rogers, MD
Ophthalmology · Chicago, ILNPI 1609042902
Payments from drug & device makers
Across 243 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$974
- Digital Diagnostics Inc.$700
- Sun Pharmaceutical Industries Inc.$613
- Kala Pharmaceuticals, Inc.$559
- Novartis$366
- plus $3K from 21 others
Across 2 payments — averaging $700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Digital Diagnostics Inc.$1K
What the payments were for
- Consulting fees$1,40020%
- Food & beverage$5,44880%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 15 | $1,113 |
| AbbVie(2 entities) | 55 | $974 |
| Digital Diagnostics Inc. | 1 | $700 |
| Sun Pharmaceutical Industries Inc. | 21 | $613 |
| Kala Pharmaceuticals, Inc. | 31 | $559 |
| Novartis | 17 | $366 |
| Bausch & Lomb Americas Inc. | 17 | $328 |
| Biotissue Holdings Inc. | 9 | $276 |
| Sight Sciences, Inc. | 4 | $266 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $265 |
| Tarsus Pharmaceuticals, Inc. | 6 | $175 |
| Harrow Eye, LLC | 6 | $170 |
| Rxsight Inc | 7 | $161 |
| Amgen(2 entities) | 7 | $159 |
| Aerie Pharmaceuticals, Inc. | 6 | $121 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $105 |
| Eyevance Pharmaceuticals LLC | 6 | $98 |
| Thea Pharma Inc. | 4 | $87 |
| Dompe US, Inc. | 3 | $70 |
| Shire North American Group Inc | 3 | $69 |
| Astellas Pharma US Inc | 2 | $47 |
| LKC Technologies, Inc. | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Akorn Operating Company LLC | 1 | $18 |
| Quidel Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$196
- Voyager DSLT$136
- LUMIGAN$124
- DURYSTA$124
- XEN GLAUCOMA TREATMENT SYSTEM$124
- CEQUA$122
- Prokera$113
- AmnioGraft$113
How this compares
$6,848 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 145 | $194,976 |
| LumiganBimatoprost | 29 | $21,662 |
| Cyclosporine | 34 | $21,571 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $12,657 |
| Latanoprost | 588 | $9,239 |
| Alphagan PBrimonidine Tartrate | 12 | $6,356 |
| Prednisolone Acetate | 148 | $6,277 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $5,570 |
| Fluorometholone | 74 | $5,565 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $4,460 |
| Travoprost | 26 | $4,367 |
| Loteprednol Etabonate | 26 | $3,940 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 202 | $3,426 |
| Timolol Maleate | 172 | $2,422 |
| ValacyclovirValacyclovir Hcl | 33 | $1,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $974 | $222,994186 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $121 | $12,65712 claims |
| AlconSimbrinza | $1,113 | $5,57014 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $265 | $3,94026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Manjot GillChicago$1.4M
- Amani FawziChicago$864K
- Sarah SunshineChicago$664K
- Jennifer LimChicago$636K
- Dilraj GrewalChicago$543K
- Ahmad ArefChicago$355K
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Armin AfsharChicago$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.